Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biocryst Pharmaceuticals Inc (BCRX) Com Stk USD 0.01

Sell:$15.37 Buy:$15.38 Change: $0.46 (3.08%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.46 (3.08%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.46 (3.08%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Contact details

4505 Emperor Blvd Ste 200
United States
+1 (919) 8591302

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.67 billion
Shares in issue:
178.87 million
United States
US dollar

Key personnel

  • Jon Stonehouse
    President, Chief Executive Officer, Director
  • Anthony Doyle
    Chief Financial Officer
  • John Bluth
    Chief Communications Officer
  • Yarlagadda Babu
    Chief Discovery Officer
  • Charles Gayer
    Chief Commercial Officer
  • William Sheridan
    Chief Medical Officer
  • Helen Thackray
    Chief Research & Development Officer
  • Alane Barnes
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.